<DOC>
	<DOCNO>NCT00572078</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability describe maximum tolerate dose ( MTD ) treatment escalate dos sorafenib combination bevacizumab paclitaxel patient advance solid tumor .</brief_summary>
	<brief_title>Sorafenib Bevacizumab Combination With Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological cytological diagnosis solid tumor evidence residual , recurrent , metastatic disease . Patients must incurable surgical standard available therapy Measurable evaluable disease ; tumor size ≥ 2 cm CT scan Patients may receive prior standard taxane therapy antiVEGF therapy , may progress therapy . Progression one type therapy ( either taxane antiVEGF ) allow History presence central nervous system ( CNS ) disease ( i.e. , primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) . Prior chemotherapy ≤ 3 week prior registration . Patients must recover therapyrelated toxicity Prior biologic immunotherapy ≤ 3 week prior registration . Patients must recover therapyrelated toxicity Prior full pelvic field radiotherapy ≤ 4 week limited field radiotherapy ≤ 2 week prior randomization . Patients must recover less equal grade 1 therapyrelated toxicity except alopecia . The site previous radiotherapy evidence progressive disease site evaluable disease Major surgery ( i.e. , laparotomy ) ≤ 4 week prior randomization anticipation need major surgical procedure course study Minor surgery ≤ 2 week prior randomization . Insertion vascular access device consider major minor surgery regard . Patients must recover surgeryrelated toxicity Peripheral neuropathy functional impairment ≥ Common Terminology Criteria ( CTC ) grade 2 neuropathy , regardless causality Pleural effusion ascites cause respiratory compromise ( ≥ CTC grade 2 dyspnea ) Concurrent severe and/or uncontrolled cardiac , vascular infectious condition ( describe protocol ) could compromise participation study Patients risk QT prolongation patient congenital long QT syndrome long correct QT ( QTc ) baseline ( i.e . QTc great 450 msec male , great 470 msec female ) exclude Lung carcinoma squamous cell histology ( mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone acceptable ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>solid tumor</keyword>
</DOC>